Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.756 USD | -1.58% | -4.57% | -3.48% |
02/04 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
29/03 | KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.48% | 19.33M | |
+31.37% | 588B | |
-2.63% | 364B | |
+20.67% | 326B | |
+5.83% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+11.19% | 167B | |
+0.05% | 161B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Northland Capital Adjusts Kala Pharmaceuticals' Price Target to $4 from $6, Keeps Outperform Rating